Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498533 | 0.90 | LMNA (0.38) | TSHRALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4502189 | 0.90 | LMNA (0.38) | TSHRALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4485134 | 0.90 | LMNA (0.38) | TSHRALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4488494 | 0.88 | CA1 (0.34) | STSCYP19A1 | |
| SCHEMBL4482535 | 0.87 | AR (0.33) | TSHRHTT | |
| SCHEMBL4484978 | 0.87 | AR (0.33) | TSHRHTT | |
| SCHEMBL4492631 | 0.82 | LMNA (0.37) | TSHRALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4497396 | 0.81 | AR (0.35) | — | |
| SCHEMBL4496438 | 0.81 | AR (0.35) | — | |
| SCHEMBL4502217 | 0.81 | AR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563793-B2 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2009-07-21 | — | — | US | claimed |
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2006-07-20 | — | — | US | claimed |
| US-7563793-B2 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006068928-A1 | PYRROLO[1,2-A]QUINOXALIN-5-(4H)-YL)SULFONYLS AND CARBONYLS AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | ESR1, GPER1, ESR2 | STS 151/4885TSHR 224/4885ALDH1A1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.